Person: GÜNDÜZ, FEYZA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
GÜNDÜZ
First Name
FEYZA
Name
26 results
Search Results
Now showing 1 - 10 of 26
Publication Open Access Evaluation of the Association between Programmed Cell Death-1 Gene Polymorphisms and Hepatocellular Carcinoma Susceptibility in Turkish Subjects. A Pilot Study(MEDICAL UNIV PRESS, 2020-10-27) EREN, FATİH; Demirci, Abdullah Fatih; Demirtas, Coskun Ozer; Eren, Fatih; Yilmaz, Demet; Keklikkiran, Caglayan; Ozdogan, Osman Cavit; Gunduz, FeyzaBackground & Aims: Programmed cell death-1 (PD-1) has a vital role in regulating T-cell function, and immune escape mechanism of cancer cells. It was shown that there could be a relationship between single nucleotide polymorphisms (SNPs) in the PD-I gene and susceptibility to hepatocellular carcinoma (MCC) based on various studies. We aimed to investigate the role of three SNPs within the PD-1 gene in susceptibility to HCC in the Turkish population. Methods: Single nucleotide polymorphisms of PD-1.1, 1.5, and 1.6 were genotyped by using TaqMan Allelic Discrimination Assays in blood samples of 137 HCC and 136 control subjects, matched for age and gender. The genotype, allele and haplotype frequencies were compared in HCC and control groups using logistic regression analysis. Results: Genotype distributions of PD-1.1, PD-1.5 and PD-1.6 SNPs were in Hardy-Weinberg equilibrium. No significant difference was observed in the genotype distribution of PD-I.1, PD-1.5 and PD-1.6 polymorphisms among gender and age-matched HCC (M/F: 96/41; mean age: 61.4 +/- 11.7 years) and control group (M/F: 94/42; mean age: 61.4 +/- 10.1). In the haplotype analysis of P1)-1.1/PD-1.5/PD-1.6, no significant difference was found among HCC and control group adjusted for sex and age (all p values>0.1). Conclusion: Our findings, firstly reporting the association of PD-1.5 polymorphism with I ICC, and PD-I.1 and PD-1.6 with HCC in the Turkish population, suggest that PD-1 polymorphisms are not predisposing factors for HCC development. Future studies with larger sample sizes and different ethnic populations are required to validate our findings.Publication Metadata only Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal Story(SPRINGER) DEMİRTAŞ, COŞKUN ÖZER; Demirtas, Coskun Ozer; Gunduz, FeyzaIn recent years, immune-based therapies have emerged as novel pillars for hepatocellular carcinoma (HCC). The rationale of immune-checkpoint inhibitors (ICIs) trial in HCC originated from the fact that the tumor cells and the infiltrating stromal and immune cells promote an immunosuppressive tumor microenvironment, including the up-regulation of immune checkpoint molecules on their surface. Antibody-based blockage targeting inhibitory checkpoint molecules on cytotoxic T cells, including programmed cell death-1 (PD-1) or its counterpart on antigen-presenting cells has shown strong anti-tumor activity in a subset of HCC patients. Single nucleotide polymorphisms (SNP) of PD-1 gene may affect the PD-1 expression or function, which eventually can cause dysfunctionality of immune balance. Based on the inhibitory role of PD-1 in anti-tumor responses, it has been investigated in several studies as a candidate to test for genetic susceptibility of individuals to HCC. The present paper highlights the knowledge on cross-talks for liver immunology and HCC course, recent studies investigating the role of functional SNPs of PD-1 gene in Turkish HCC population, and the data on already investigated PD-1 inhibitor molecules in clinical trials.Publication Metadata only No association of PTPN22 gene polymorphism with rheumatoid arthritis in Turkey(SPRINGER HEIDELBERG, 2009) GÜNDÜZ, FEYZA; Sahin, N.; Gunduz, F.; Inanc, N.; Direskeneli, Haner; Saruhan-Direskeneli, G.Although the association of rheumatoid arthritis (RA) with HLA-DRB1 (shared epitope) is well demonstrated in many ethnic populations, the role of other RA-associated risk loci is not clarified. In this study, the functional single nucleotide polymorphism (SNP) of PTPN22 gene was investigated in Turkey. 167 patients with RA and 177 healthy controls are genotyped by polymerase chain reaction (PCR)-RFLP for the SNP (rs2476601, A/G) of PTPN22 gene. Polymorphic region was amplified by PCR and digested with Xcm I enzyme. Heterozygous genotype (AG) was present in 5.1% (9/177) of the controls and in 6.6% (11/167) of RA group (p = 0.55, OR 1.3, 95% CI 0.53-3.26). There was also no association between any clinical feature, RF positivity and presence of this SNP. In conclusion, the distribution of PTPN22 polymorphism did not reveal any association with RA in Turkey.Publication Open Access Radiological quantification of sarcopenic obesity and its role in chronic liver disease severity(2023-04-01) ÇİMŞİT, CANAN; KURŞUN, MELTEM; DEMİRCİOĞLU, ÖZLEM; GÜNDÜZ, FEYZA; DEMİRTAŞ, COŞKUN ÖZER; Çimşit C., Kurşun M., Demircioğlu Ö., Dilber F., Demirtaş C. Ö., Ergenç İ.Publication Metadata only Sertraline Hepatotoxicity: Report of a Case and Review of the Literature(SPRINGER, 2009) GÜNDÜZ, FEYZA; Tabak, Fehmi; Gunduz, Feyza; Tahan, Veysel; Tabak, Omur; Ozaras, ResatSertraline is a commonly prescribed selective serotonin reuptake inhibitor drug. Hepatotoxicity caused by sertraline is rare. Asymptomatic elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels have been rarely reported and shortly normalize after discontinuation of the agent. We present a case of severe drug-induced hepatitis in a patient receiving sertraline. To our knowledge, this is the seventh case in the medical literature as being associated with severe hepatotoxicity. Since it is extremely rare, we do not suggest a strict laboratory monitoring. However, sertraline should be discontinued in cases with symptoms implying hepatotoxicity and the patients should be informed of the potential of this side effect.Publication Open Access Surveillance Strategies for Hepatocellular Carcinoma: Recent Advances and the Shifting Paradigm(SPRINGER, 2021-12) DEMİRTAŞ, COŞKUN ÖZER; Demirtas, Coskun Ozer; Gunduz, Feyza; Ozdogan, Osman CavitCurrently, international liver societies recommend screening at-risk individuals for HCC (patients with cirrhosis regardless of etiology, and/or chronic hepatitis B virus, and/or advanced liver fibrosis) with biannual abdominal ultrasound (USG) with or without alpha-fetoprotein (AFP). The global acceptance of USG in surveillance relies on the absence of risks, non-invasiveness, and lower costs. However, the suboptimal performance of USG +/- AFP in reaching direct and indirect goals of HCC surveillance highlights the need for alternative surveillance strategies. Several studies targeted contrast-enhanced magnetic resonance imaging techniques, but the main barriers for their entrance to surveillance programs have been concerns about cost-effectivity and long scan times. Overall, the HCC risk stratification appears at hand by several validated multiple score systems, but their optimal performance is obtained only in populations who show highly homogenous clinical, pathological, epidemiologic, etiologic, and therapeutic characteristics, and this limitation poses a major drawback to their sustainable use in clinical practice. We need globally validated and molecular integrated risk stratification tools to shape the future tailored HCC surveillance decision algorithms. A dynamic process for HCC surveillance algorithms awaits us owing to the expected further prospective studies focusing on risk-stratified screening strategy.Publication Metadata only Siroz hastalarında hepatosellüler karsinom taramasında altı ayda bir yapılan batın ultrasonografi ve serum alfa-feto protein ölçümüne ek olarak, yılda bir kez yapılan batın manyetik rezonans görüntülemesinin erken tanıya olan katkısı(2006-10-11) BUĞDAYCI, ONUR; GÜNDÜZ, FEYZA; ÖZDOĞAN, OSMAN CAVİT; TÜNEY, DAVUT; BUĞDAYCI O., Sever A., DİLBER F., KEDRAH A. E., TİFTİKÇİ A., AKIN H., ERZEN T. C., TÖZÜN A. N., ÖZDOĞAN O. C., TÜNEY D.Publication Metadata only The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort(2023-01-01) GÜNDÜZ, FEYZA; Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., Kurtulmus I. A., Kayhan M. A., Vatansever S., ADANIR H., et al.Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per protocol analysis. The SVR12 rates were statistically significant differences between the patients who were i.v. drug users and non-user (88.0% vs. 98.8%, p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p<0.001 and p=0.014, respectively). No severe adverse effect was observed. Conclusion: GLE/PIB is an effective and tolerable treatment in patients with CHC.Publication Metadata only Letter: Is female sex an independent predictor of favourable prognosis in hepatocellular carcinoma?(WILEY, 2020) DEMİRTAŞ, COŞKUN ÖZER; Demirtas, Coskun Ozer; Gunduz, FeyzaPublication Open Access Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index(2022-09-01) DEMİRTAŞ, COŞKUN ÖZER; ÖZDOĞAN, OSMAN CAVİT; BALTACIOĞLU, FEYYAZ; ÖNEŞ, TUNÇ; YUMUK, PERRAN FULDEN; DULUNDU, ENDER; GÜNDÜZ, FEYZA; DEMİRTAŞ C. Ö. , Ricco G., ÖZDOĞAN O. C. , BALTACIOĞLU F., ÖNEŞ T., YUMUK P. F. , DULUNDU E., Uzun S., Colombatto P., Oliveri F., et al.
- «
- 1 (current)
- 2
- 3
- »